<DOC>
	<DOC>NCT00924534</DOC>
	<brief_summary>The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SLV337 in patients with type 2 diabetes</brief_summary>
	<brief_title>A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion Criteria Type 2 diabetes ,stable dose of Metformin,HbA1c &gt;= 7%, but &lt; 9% Exclusion Criteria Type 1 diabetes mellitus, Body Mass Index (BMI) &gt;40.0 kg/m2, evidence of unstable cardiovascular diseases, NYHA class I to IV, ALT &gt; 1.5 times UNL, creatinine clearance &lt;60 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>interventional</keyword>
	<keyword>placebo</keyword>
	<keyword>controlled</keyword>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
	<keyword>safety</keyword>
</DOC>